person · Reporting owner

JONES EVAN/ FA

Disclosed activity across 4 companies

Tapewire entity: 38344
SEC CIK: 0001020741

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CapForce Inc.OPGN · Entity 9776	Director	May 17, 2021	May 19, 2021
STANDARD BIOTOOLS INC.FLDM · Entity 6116	Director	July 31, 2017	August 03, 2017
VERACYTE, INC.VCYT · Entity 2018	Director	June 11, 2026	June 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CapForce Inc.

Report date May 17, 2021 · Filed May 19, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	22,617	Reported balance After 2021-05-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-05-17 · Exercise / conversion · Acquired 883 · Balance 22,617 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	884	Reported balance After 2021-05-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-05-17 · Exercise / conversion · Disposed 883 · Balance 884 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant.

Filing footnotes · ownership attribution and instrument terms

F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019.

F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis.

F3: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant.

STANDARD BIOTOOLS INC.

Report date July 31, 2017 · Filed August 03, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy jVen Capital, LLC	58,551	Reported balance After 2017-07-31 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-07-31 · Exercise / conversion · Acquired 5,000 · Balance 58,551 F1: The reporting person is managing member of jVen Capital, LLC.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2017-07-31	Direct	0	Reported balance After 2017-07-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-07-31 · Exercise / conversion · Disposed 5,000 · Balance 0 F2: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person is managing member of jVen Capital, LLC.

F2: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit.

VERACYTE, INC.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	34,634	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 5,272 · Balance 34,634 F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Foundation Medicine, Inc.

Report date July 31, 2018 · Filed August 02, 2018

Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-07-31 transaction · row 1 1 source row Row 1 · 2018-07-31 · Other · Disposed 17,652 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.
Common StockSEC Table I · non-derivative	Indirectby jVen Capital LLC	Reported balance After 2018-07-31 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-07-31 · Other · Disposed 9,300 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of shares sold by the reporting person in connection with the tender offer for shares of Common Stock of the Issuer (the "Tender Offer") by Roche Holdings, Inc. ("Roche").
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2023-03-07	Direct	Reported balance After 2018-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-31 · Other · Disposed 6,252 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: This option was granted on March 7, 2013 and vested in sixteen equal quarterly installments thereafter, ending on January 10, 2017.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.21 · Expires 2024-06-18	Direct	Reported balance After 2018-07-31 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-31 · Other · Disposed 13,385 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.
stock option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2023-05-22	Direct	Reported balance After 2018-07-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-07-31 · Other · Disposed 4,922 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F5: This stock option was granted on May 22, 2013 and vested in sixteen equal quarterly installments thereafter, ending on May 22, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.

F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.

F3: The amount reported represents the number of shares sold by the reporting person in connection with the tender offer for shares of Common Stock of the Issuer (the "Tender Offer") by Roche Holdings, Inc. ("Roche").

F4: This option was granted on March 7, 2013 and vested in sixteen equal quarterly installments thereafter, ending on January 10, 2017.

F5: This stock option was granted on May 22, 2013 and vested in sixteen equal quarterly installments thereafter, ending on May 22, 2017.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 11, 2022 Filed Nov 15, 2022 21:54 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	5,900	$30.21	$178,254.93	Disclosure SEC source: 0001384101-22-000143 · wf-form4_166854926790911.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,551 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2022. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.945. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document
June 16, 2022 Filed Jun 17, 2022 00:06 UTC	VERACYTE, INC. VCYT · Entity 2018	GrantCommon Stock	14,731	$0.00	$0.00	Disclosure SEC source: 0001384101-22-000090 · wf-form4_165542436759261.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,451 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:51 UTC	VERACYTE, INC. VCYT · Entity 2018	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $4.00	$0.00	Disclosure SEC source: 0001384101-22-000009 · wf-form4_164211068307265.xml · derivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:51 UTC	VERACYTE, INC. VCYT · Entity 2018	Exercise / conversionCommon Stock	5,000	$4.00	$20,000.00	Disclosure SEC source: 0001384101-22-000009 · wf-form4_164211068307265.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 08, 2021 Filed Jun 10, 2021 20:16 UTC	VERACYTE, INC. VCYT · Entity 2018	GrantCommon Stock	8,720	$0.00	$0.00	Disclosure SEC source: 0001384101-21-000111 · wf-form4_162335616180777.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,720 F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document
May 17, 2021 Filed May 19, 2021 20:47 UTC	CapForce Inc. OPGN · Entity 9776	Exercise / conversionRestricted Stock Units · Derivative	883	$0.00	$0.00	Disclosure SEC source: 0001079973-21-000401 · ownership.xml · derivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884 Underlying: Common Stock · 883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2 · derivative.exercise_price: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. F3 · derivative.expiration_date: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. Read SEC document
May 17, 2021 Filed May 19, 2021 20:47 UTC	CapForce Inc. OPGN · Entity 9776	Exercise / conversionCommon Stock	883	$0.00	$0.00	Disclosure SEC source: 0001079973-21-000401 · ownership.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. Read SEC document
January 22, 2021 Filed Jan 25, 2021 22:24 UTC	VERACYTE, INC. VCYT · Entity 2018	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.36	$0.00	Disclosure SEC source: 0001384101-21-000002 · wf-form4_161161348034724.xml · derivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
January 22, 2021 Filed Jan 25, 2021 22:24 UTC	VERACYTE, INC. VCYT · Entity 2018	Exercise / conversionCommon Stock	5,000	$2.36	$11,800.00	Disclosure SEC source: 0001384101-21-000002 · wf-form4_161161348034724.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 27, 2020 Filed Oct 29, 2020 20:33 UTC	CapForce Inc. OPGN · Entity 9776	SaleCommon Stock	1,748	$2.35	$4,107.80	Disclosure SEC source: 0001079973-20-000906 · ownership.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 21,734 F1 · ownership.direct: The securities are directly held by jVen Capital, LLC ("jVen Capital"). Mr. Jones is managing member of jVen Capital and may be deemed to have voting and dispositive power over the shares owned by jVen Capital. Read SEC document
September 30, 2020 Filed Oct 2, 2020 21:41 UTC	CapForce Inc. OPGN · Entity 9776	GrantStock Option Award · Derivative	50,000	$0.00 Strike: $2.12	$0.00	Disclosure SEC source: 0001079973-20-000845 · ownership.xml · derivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The grant of stock options have a one-year vesting schedule, vesting quarterly in equal installments on the first day of each three month period, as long as the Reporting Person continues providing services to the Company on each such vesting date. Read SEC document
September 04, 2020 Filed Sep 9, 2020 21:31 UTC	CapForce Inc. OPGN · Entity 9776	SaleCommon Stock	3,612	$2.19	$7,910.28	Disclosure SEC source: 0001079973-20-000778 · ownership.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 23,482 F1 · price: The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.11 to $2.23 inclusive. The reporting person undertakes to provide to OpGen, Inc., any security holder of OpGen, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.direct: The securities are directly held by jVen Capital, LLC ("jVen Capital"). Mr. Jones is managing member of jVen Capital and may be deemed to have voting and dispositive power over the shares owned by jVen Capital Read SEC document
August 03, 2020 Filed Aug 4, 2020 23:59 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	1,200	$35.60	$42,714.48	Disclosure SEC source: 0001437749-20-016558 · rdgdoc.xml · nonDerivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 69,653 F5 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2020. F7 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.50 to $35.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
August 03, 2020 Filed Aug 4, 2020 23:59 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	18,800	$35.13	$660,402.64	Disclosure SEC source: 0001437749-20-016558 · rdgdoc.xml · nonDerivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 70,853 F5 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2020. F6 · price: Represents weighted average sales price. Sale prices for the transactions range from $34.49 to $35.49. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
July 31, 2020 Filed Aug 4, 2020 23:59 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	3,520	$36.16	$127,280.38	Disclosure SEC source: 0001437749-20-016558 · rdgdoc.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 89,653 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $36.05 to $36.34. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
July 31, 2020 Filed Aug 4, 2020 23:59 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	16,480	$35.56	$586,025.50	Disclosure SEC source: 0001437749-20-016558 · rdgdoc.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 93,173 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.04 to $36.04. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
July 15, 2020 Filed Jul 16, 2020 21:15 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	3,700	$30.65	$113,413.14	Disclosure SEC source: 0001437749-20-015296 · rdgdoc.xml · nonDerivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 109,653 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F6 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.49 to $30.91. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
July 15, 2020 Filed Jul 16, 2020 21:15 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	6,300	$29.81	$187,779.06	Disclosure SEC source: 0001437749-20-015296 · rdgdoc.xml · nonDerivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 113,353 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F5 · price: Represents weighted average sales price. Sale prices for the transactions range from $29.45 to $30.45. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
July 14, 2020 Filed Jul 16, 2020 21:15 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	7,600	$28.69	$218,071.36	Disclosure SEC source: 0001437749-20-015296 · rdgdoc.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 119,653 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.52 to $29.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
July 14, 2020 Filed Jul 16, 2020 21:15 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	12,400	$28.13	$348,776.04	Disclosure SEC source: 0001437749-20-015296 · rdgdoc.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 127,253 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $27.51 to $28.51. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
June 08, 2020 Filed Jun 9, 2020 20:30 UTC	VERACYTE, INC. VCYT · Entity 2018	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $26.30	$0.00	Disclosure SEC source: 0001384101-20-000087 · wf-form4_159173461625244.xml · derivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on June 8, 2021 or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document
May 17, 2020 Filed May 20, 2020 00:37 UTC	CapForce Inc. OPGN · Entity 9776	Exercise / conversionRestricted Stock Units · Derivative	883	$0.00	$0.00	Disclosure SEC source: 0001079973-20-000439 · ownership.xml · derivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,767 Underlying: Common Stock · 883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2 · derivative.exercise_price: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant. F3 · derivative.expiration_date: On May 17, 2019, the Reporting Person was granted 2,650 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant. Read SEC document
May 17, 2020 Filed May 20, 2020 00:37 UTC	CapForce Inc. OPGN · Entity 9776	Exercise / conversionCommon Stock	883	$0.00	$0.00	Disclosure SEC source: 0001079973-20-000439 · ownership.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. Read SEC document
January 16, 2020 Filed Jan 21, 2020 21:25 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	14,049	$30.11	$422,974.65	Disclosure SEC source: 0001384101-20-000008 · wf-form4_157964189937684.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 139,653 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.19. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
January 14, 2020 Filed Jan 15, 2020 21:54 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	300	$28.93	$8,679.99	Disclosure SEC source: 0001384101-20-000004 · wf-form4_157912522352347.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 153,702 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.91 to $28.95. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
January 14, 2020 Filed Jan 15, 2020 21:54 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	4,700	$28.48	$133,841.43	Disclosure SEC source: 0001384101-20-000004 · wf-form4_157912522352347.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 154,002 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $27.91 to $28.87. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
December 17, 2019 Filed Dec 18, 2019 21:37 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	15,000	$29.26	$438,865.50	Disclosure SEC source: 0001384101-19-000168 · wf-form4_157670504870918.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 158,702 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.97 to $29.54. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
December 06, 2019 Filed Dec 9, 2019 21:19 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	800	$30.03	$24,022.48	Disclosure SEC source: 0001384101-19-000164 · wf-form4_157592633992380.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 173,702 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.06. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
December 05, 2019 Filed Dec 9, 2019 21:19 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	5,151	$30.00	$154,535.15	Disclosure SEC source: 0001384101-19-000164 · wf-form4_157592633992380.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 174,502 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.000 to $30.005. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
November 11, 2019 Filed Nov 13, 2019 20:46 UTC	CapForce Inc. OPGN · Entity 9776	SaleCommon Stock	6,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001079973-19-000584 · ownership.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 26,211 F1 · price: The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.375 inclusive. The reporting person undertakes to provide to OpGen, Inc., any security holder of OpGen, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: The securities are directly held by jVen Capital, LLC ("jVen Capital"). Mr. Jones is managing member of jVen Capital and may be deemed to have voting and dispositive power over the shares owned by jVen Capital. F2 · ownership.nature: The securities are directly held by jVen Capital, LLC ("jVen Capital"). Mr. Jones is managing member of jVen Capital and may be deemed to have voting and dispositive power over the shares owned by jVen Capital. Read SEC document
August 28, 2019 Filed Aug 29, 2019 20:32 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	6,600	$26.10	$172,290.36	Disclosure SEC source: 0001384101-19-000110 · wf-form4_156711072707256.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 179,653 F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.95 to $26.39. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F2 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
August 27, 2019 Filed Aug 29, 2019 20:32 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	3,400	$26.11	$88,760.40	Disclosure SEC source: 0001384101-19-000110 · wf-form4_156711072707256.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 186,253 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $26.00 to $26.25. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F2 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
August 09, 2019 Filed Aug 12, 2019 20:24 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	15,000	$26.38	$395,680.50	Disclosure SEC source: 0001384101-19-000104 · wf-form4_156564147451154.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 189,653 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $26.13 to $26.61. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F2 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
June 12, 2019 Filed Jun 13, 2019 20:43 UTC	VERACYTE, INC. VCYT · Entity 2018	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $27.01	$0.00	Disclosure SEC source: 0001384101-19-000076 · wf-form4_156045858803088.xml · derivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option becomes exercisable in full on June 12, 2020 or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document
May 17, 2019 Filed May 20, 2019 21:19 UTC	CapForce Inc. OPGN · Entity 9776	GrantRestricted Stock Units · Derivative	53,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001079973-19-000316 · ownership.xml · derivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to acquire one share of Common Stock. F2 · derivative.exercise_date: The restricted stock units are subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. F2 · derivative.expiration_date: The restricted stock units are subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. Read SEC document
March 28, 2019 Filed Apr 1, 2019 18:52 UTC	CapForce Inc. OPGN · Entity 9776	PurchaseCommon Stock	417,000	$0.60	$250,200.00	Disclosure SEC source: 0001567619-19-007942 · doc1.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 644,138 F1 · ownership.nature: Purchase by jVen Capital, LLC in public offering. Mr. Jones is the managing member of jVen Capital, LLC. Read SEC document
February 28, 2019 Filed Mar 5, 2019 00:11 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	75,000	$20.37	$1,527,802.50	Disclosure SEC source: 0001384101-19-000026 · wf-form4_155174465446131.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 204,653 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $20.03 to $20.90. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F2 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Otherstock option (right to buy) · Derivative	13,385	$0.00 Strike: $24.21	$0.00	Disclosure SEC source: 0001209191-18-044928 · doc4.xml · derivative · entry 5 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,385 shares Expires 2024-06-18 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Otherstock option (right to buy · Derivative	4,922	$0.00 Strike: $7.12	$0.00	Disclosure SEC source: 0001209191-18-044928 · doc4.xml · derivative · entry 4 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,922 shares Expires 2023-05-22 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F5 · derivative.exercise_date: This stock option was granted on May 22, 2013 and vested in sixteen equal quarterly installments thereafter, ending on May 22, 2017. Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Otherstock option (right to buy) · Derivative	6,252	$0.00 Strike: $4.16	$0.00	Disclosure SEC source: 0001209191-18-044928 · doc4.xml · derivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,252 shares Expires 2023-03-07 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4 · derivative.exercise_date: This option was granted on March 7, 2013 and vested in sixteen equal quarterly installments thereafter, ending on January 10, 2017. Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	9,300	$137.00	$1,274,100.00	Disclosure SEC source: 0001209191-18-044928 · doc4.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital LLC Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3 · shares: The amount reported represents the number of shares sold by the reporting person in connection with the tender offer for shares of Common Stock of the Issuer (the "Tender Offer") by Roche Holdings, Inc. ("Roche"). Read SEC document
July 31, 2018 Filed Aug 2, 2018 20:07 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	17,652	$137.00	$2,418,324.00	Disclosure SEC source: 0001209191-18-044928 · doc4.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2 · shares: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Read SEC document
June 07, 2018 Filed Jun 7, 2018 21:20 UTC	VERACYTE, INC. VCYT · Entity 2018	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $7.60	$0.00	Disclosure SEC source: 0001384101-18-000046 · wf-form4_152840642626768.xml · derivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document
May 24, 2018 Filed May 29, 2018 20:06 UTC	VERACYTE, INC. VCYT · Entity 2018	Exercise / conversionStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $0.08	$0.00	Disclosure SEC source: 0001384101-18-000032 · wf-form4_152762437631462.xml · derivative · entry 3 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2018-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option award is immediately exercisable and fully vested. Read SEC document
May 24, 2018 Filed May 29, 2018 20:06 UTC	VERACYTE, INC. VCYT · Entity 2018	Exercise / conversionCommon Stock	25,000	$0.08	$2,000.00	Disclosure SEC source: 0001384101-18-000032 · wf-form4_152762437631462.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 23, 2018 Filed Jan 25, 2018 22:00 UTC	CapForce Inc. OPGN · Entity 9776	GrantStock Option Award · Derivative	21,000	$0.00 Strike: $4.02	$0.00	Disclosure SEC source: 0001140361-18-003236 · doc1.xml · derivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The options vest 25% on January 23, 2019 and 6.25% on the quarterly anniversary of the first vesting date for a period of three years. Read SEC document
December 13, 2017 Filed Dec 15, 2017 21:02 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,400	$62.05	$86,870.00	Disclosure SEC source: 0001209191-17-065888 · doc4.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,652 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.05 to $62.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
December 06, 2017 Filed Dec 7, 2017 21:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	600	$57.88	$34,728.00	Disclosure SEC source: 0001209191-17-064389 · doc4.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,052 F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.55 to $58.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
December 05, 2017 Filed Dec 7, 2017 21:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	5,900	$60.94	$359,546.00	Disclosure SEC source: 0001209191-17-064389 · doc4.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,652 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $61.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
August 28, 2017 Filed Aug 29, 2017 20:07 UTC	VERACYTE, INC. VCYT · Entity 2018	SaleCommon Stock	2,500	$7.84	$19,600.00	Disclosure SEC source: 0001384101-17-000056 · wf-form4_150403726119951.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 279,653 F2 · price: Reporting Person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a security holder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sales price. Actual sale prices ranged from $7.77 to $7.935. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.